Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.

Smith RP, Khanna A, Coward RM, Rajanahally S, Kovac JR, Gonzales MA, Lipshultz LI.

J Sex Med. 2013 Sep;10(9):2326-33. doi: 10.1111/jsm.12226. Epub 2013 Jul 16.

PMID:
23859250
2.

Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI.

J Sex Med. 2014 Feb;11(2):553-62. doi: 10.1111/jsm.12369. Epub 2013 Nov 6.

3.

Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.

Taylor F, Levine L.

J Sex Med. 2010 Jan;7(1 Pt 1):269-76. doi: 10.1111/j.1743-6109.2009.01454.x. Epub 2009 Aug 17.

PMID:
19694928
5.

Long-term treatment patterns of testosterone replacement medications.

Donatucci C, Cui Z, Fang Y, Muram D.

J Sex Med. 2014 Aug;11(8):2092-9. doi: 10.1111/jsm.12608. Epub 2014 Jun 9.

PMID:
24909541
6.

Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.

Reyes-Vallejo L, Lazarou S, Morgentaler A.

J Sex Med. 2007 Nov;4(6):1757-62. Epub 2006 Nov 6.

PMID:
17087806
7.

Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.

Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.

Int J Impot Res. 2008 Mar-Apr;20(2):213-7. Epub 2007 Sep 27.

PMID:
17898800
8.

Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome.

Moskovic DJ, Freundlich RE, Yazdani P, Lipshultz LI, Khera M.

J Androl. 2012 Jul-Aug;33(4):570-3. doi: 10.2164/jandrol.111.013979. Epub 2011 Sep 22.

PMID:
21940986
9.

Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.

Schoenfeld MJ, Shortridge E, Cui Z, Muram D.

J Sex Med. 2013 May;10(5):1401-9. doi: 10.1111/jsm.12114. Epub 2013 Mar 6.

PMID:
23464534
10.

Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.

Morrison BF, Reid M, Madden W, Burnett AL.

Andrology. 2013 Jul;1(4):576-82. doi: 10.1111/j.2047-2927.2013.00084.x. Epub 2013 Apr 18.

11.

Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.

Conaglen HM, Paul RG, Yarndley T, Kamp J, Elston MS, Conaglen JV.

J Sex Med. 2014 Feb;11(2):574-82. doi: 10.1111/jsm.12401. Epub 2013 Nov 27.

PMID:
24279472
13.

Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.

Pastuszak AW, Mittakanti H, Liu JS, Gomez L, Lipshultz LI, Khera M.

J Androl. 2012 Sep-Oct;33(5):927-37. Epub 2012 Mar 8.

PMID:
22403285
14.

Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.

Cavender RK, Fairall M.

J Sex Med. 2009 Nov;6(11):3177-92. doi: 10.1111/j.1743-6109.2009.01513.x. Epub 2009 Sep 29.

PMID:
19796052
15.

Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.

Liao CH, Wu YN, Lin FY, Tsai WK, Liu SP, Chiang HS.

Andrology. 2013 Jul;1(4):563-9. doi: 10.1111/j.2047-2927.2013.00086.x. Epub 2013 May 8.

16.

A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.

McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA.

J Sex Med. 2012 Feb;9(2):594-601. doi: 10.1111/j.1743-6109.2011.02570.x. Epub 2012 Jan 12.

PMID:
22240203
17.

Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).

Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM.

Clin Interv Aging. 2012;7:321-30. doi: 10.2147/CIA.S32036. Epub 2012 Aug 24.

18.

Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden.

Arver S, Luong B, Fraschke A, Ghatnekar O, Stanisic S, Gultyev D, Müller E.

J Sex Med. 2014 Jan;11(1):262-72. doi: 10.1111/jsm.12277. Epub 2013 Aug 12. Review.

PMID:
23937088
19.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.

20.

Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy.

Ramasamy R, Scovell JM, Kovac JR, Lipshultz LI.

J Urol. 2014 Sep;192(3):875-9. doi: 10.1016/j.juro.2014.03.089. Epub 2014 Mar 21.

PMID:
24657837
Items per page

Supplemental Content

Write to the Help Desk